Financial Performance - The company's revenue for Q3 2022 reached ¥1,048,169,275.61, representing a 108.26% increase year-over-year[8] - Net profit attributable to shareholders was ¥173,770,427.59, up 119.46% compared to the same period last year[8] - The basic earnings per share (EPS) for the quarter was ¥0.4338, reflecting a 93.06% increase year-over-year[8] - Revenue for Q3 2022 reached CNY 3,108,826,470.97, a 143.91% increase compared to CNY 1,274,585,137.05 in the same period last year[12] - The company’s net profit attributable to shareholders increased by 84.38% to CNY 1,057,958,789.69, reflecting improved profitability[12] - Net profit for the third quarter was ¥732,923,590.45, up from ¥225,095,776.79 in the same quarter last year, reflecting an increase of approximately 226%[26] - The net profit attributable to the parent company shareholders for Q3 2022 was ¥604,318,752.27, a significant increase of 240.5% compared to ¥177,362,492.54 in the same period last year[27] - The total comprehensive income for Q3 2022 reached ¥732,923,590.45, up from ¥225,095,776.79 in Q3 2021, reflecting a growth of 225.5%[27] - The basic and diluted earnings per share for Q3 2022 were both ¥1.5088, compared to ¥0.5032 in Q3 2021, marking an increase of 199.4%[27] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,548,942,599.38, a 68.56% increase from the end of the previous year[8] - Current assets totaled ¥3,048,993,570.23, a significant rise from ¥1,767,073,343.02 at the start of the year, representing an increase of approximately 72%[23] - Accounts receivable increased by 196.77% to CNY 2,357,343,761.93, primarily due to rapid business growth and longer collection periods for nucleic acid testing services[12] - Current liabilities increased to ¥1,235,928,530.79 from ¥412,984,007.32, showing a growth of about 199%[23] - Other current liabilities decreased by 50.17% to CNY 504,858.44, primarily due to a reduction in customer prepayments[12] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥244,928,430.49, indicating a significant decline of 366.01%[8] - The company reported a net cash outflow from operating activities of CNY -244,928,430.49, a 366.01% decrease compared to CNY -52,558,365.95 in the previous year, attributed to longer collection periods[13] - Cash inflows from operating activities amounted to ¥1,617,943,810.66, compared to ¥1,008,192,482.15 in the previous year, representing a growth of 60.5%[30] - The net cash flow from operating activities was negative at ¥-244,928,430.49, worsening from ¥-52,558,365.95 in the same period last year[30] - Cash inflows from investment activities totaled ¥712,637,944.43, significantly higher than ¥193,242,445.52 in Q3 2021, indicating an increase of 269.5%[30] - The net cash flow from investment activities was positive at ¥223,651,695.06, compared to a negative cash flow of ¥-117,042,737.52 in the previous year[30] - The net cash flow from financing activities was ¥1,013,171.26, a decrease from ¥165,579,634.56 in Q3 2021[31] - The cash and cash equivalents at the end of Q3 2022 were ¥330,756,477.89, down from ¥348,177,024.79 at the end of Q3 2021[31] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,068, with no preferred shareholders[15] - The company had a total of 140,587,892 shares (accounting for 35.10% of the total share capital) released for trading on September 13, 2022, from previously issued shares and strategic placement shares[19] - The top 10 shareholders include Hailan Group Co., Ltd. with 42,900,000 shares, accounting for a significant portion of the company's equity[18] - The company plans to issue A-shares to specific investors as approved in the board and shareholder meetings held in September 2022[19] - The company has a total of 357,261,200 shares with 221,552,568 shares remaining under lock-up as of the report date[18] - The company reported a total of 149,554,017 shares under lock-up prior to the IPO, which will be released on September 13, 2024[17] - The company’s major shareholder, Zeng Weixiong, holds 53,769,291 shares, which are also under lock-up until September 13, 2024[17] Research and Development - R&D expenses rose by 110.16% to CNY 48,323,302.30, reflecting significant investment in research projects during the reporting period[13] - Research and development expenses for the quarter were ¥48,323,302.30, compared to ¥22,993,309.05 in the previous year, indicating an increase of about 110%[26] - The company is actively involved in research and development of new technologies to improve its service offerings[21] Strategic Initiatives - The company’s financial report indicates a focus on expanding its market presence and enhancing its product offerings[21] - The company has engaged in strategic partnerships to bolster its investment capabilities and market reach[21] Operating Costs - Total operating costs amounted to ¥2,187,490,828.03, compared to ¥1,004,403,638.49 in the previous year, indicating a year-over-year increase of about 118%[26] - Gross profit margin decreased as operating costs increased by 126.05% to CNY 1,748,303,570.91, driven by higher business volume[12]
兰卫医学(301060) - 2022 Q3 - 季度财报